Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030) by Linker, Condition, End Use and Region - Industry Set to Experience 11.8% CAGR Over the Forecast Period
22. November 2024 07:14 ET
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030" report has been added to ...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
07. November 2024 08:30 ET
|
Vaccinex, Inc.
Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Antibody Drug Conjugates (ADC) Industry Report 2024 - Advancements in Payload and Linker Technologies Generate Opportunities for Innovative ADC Products
05. November 2024 05:31 ET
|
Research and Markets
Dublin, Nov. 05, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates (ADC) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Antibody...
Antibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche., Daiichi Sankyo, Pfizer, and Gilead Sciences
04. November 2024 07:00 ET
|
Research and Markets
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global sales of ADCs on...
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - A US$ 50 Billion+ Market Opportunity By 2030
31. Oktober 2024 12:57 ET
|
Research and Markets
Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ...
Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24. Oktober 2024 10:12 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides...
Bispecific Antibody Drug Conjugates Market Opportunity Outlook 2024-2029: China Leads Over 35 Candidates, Key Companies Pioneering BsADC are Amgen, Innovent Biologics, AstraZeneca
14. Oktober 2024 05:52 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to...
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 Players - ADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More
09. Oktober 2024 10:13 ET
|
Research and Markets
Dublin, Oct. 09, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Report by Component, Target, Application, End-user, and Region 2024-2032" report has been added to ...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14. September 2024 03:00 ET
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
Degrader-Antibody Conjugates (DAC) Landscape Report 2024: Stakeholders, Platform Technologies, Development and Discovery Pipelines and Partnering Deals
10. September 2024 12:36 ET
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective" report...